IntraCellular Therapies (ITCI)
(Delayed Data from NSDQ)
$68.54 USD
+0.55 (0.81%)
Updated Jul 2, 2024 04:00 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Cash flow Statements
Fiscal Year End for IntraCellular Therapies Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -139.67 | -256.26 | -284.13 | -227.01 | -147.72 |
Depreciation/Amortization & Depletion | -7.87 | 1.10 | -3.55 | -0.12 | -0.65 |
Net Change from Assets/Liabilities | -29.58 | -58.14 | -6.35 | -27.54 | -0.85 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 52.92 | 43.10 | 34.48 | 24.59 | 21.25 |
Net Cash From Operating Activities | -124.20 | -270.19 | -259.54 | -230.07 | -127.98 |
Property & Equipment | -0.27 | -0.78 | -0.33 | -0.27 | -0.70 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 105.81 | -127.60 | 280.67 | -480.03 | 178.14 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 105.54 | -128.37 | 280.34 | -480.30 | 177.44 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 17.81 | 455.16 | 11.52 | 664.18 | 3.24 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 17.81 | 455.16 | 11.52 | 664.18 | 3.24 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -0.85 | 56.60 | 32.32 | -46.19 | 52.69 |
Cash at Beginning of Period | 150.37 | 93.77 | 61.45 | 107.64 | 54.95 |
Cash at End of Period | 149.52 | 150.37 | 93.76 | 61.45 | 107.64 |
Diluted Net EPS | -1.46 | -2.72 | -3.50 | -3.23 | -2.68 |
Fiscal Year End for IntraCellular Therapies Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -15.25 | -139.67 | -111.10 | -86.84 | -44.05 |
Depreciation/Amortization & Depletion | -2.21 | -7.87 | -5.47 | -3.41 | -1.60 |
Net Change from Assets/Liabilities | -30.52 | -29.58 | -43.62 | -30.33 | -24.87 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 13.87 | 52.92 | 38.05 | 23.71 | 10.46 |
Net Cash From Operating Activities | -34.12 | -124.20 | -122.14 | -96.87 | -60.07 |
Property & Equipment | 0.00 | -0.27 | -0.27 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 16.18 | 105.81 | 58.39 | 78.29 | -16.46 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 16.18 | 105.54 | 58.12 | 78.29 | -16.46 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 9.99 | 17.81 | 14.81 | 12.23 | 3.64 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 9.99 | 17.81 | 14.81 | 12.23 | 3.64 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -7.95 | -0.85 | -49.21 | -6.36 | -72.89 |
Cash at Beginning of Period | 149.52 | 150.37 | 150.37 | 150.37 | 150.37 |
Cash at End of Period | 141.57 | 149.52 | 101.15 | 144.01 | 77.48 |
Diluted Net EPS | -0.16 | -0.30 | -0.25 | -0.45 | -0.46 |